Does Anthem (Elevance Health) Cover Prometrium?

What Is Prometrium and Why Is It Prescribed?

Prometrium is the brand-name formulation of oral micronized progesterone (100 mg and 200 mg capsules suspended in peanut oil). The FDA approved it for two indications: secondary amenorrhea and protection of the endometrial lining in postmenopausal women receiving conjugated estrogens [1]. Prescribers also use it off-label for perimenopausal sleep disturbance, luteal-phase support in fertility protocols, and transgender hormone therapy, though insurance coverage for off-label uses is significantly narrower.

The clinical rationale for using micronized progesterone rather than synthetic progestogens is well-supported. The landmark Postmenopausal Estrogen/Progestin Interventions (PEPI) trial (N=875, mean follow-up 3 years) found that women assigned to conjugated equine estrogen plus micronized progesterone showed the most favorable lipid profile changes among all active-treatment arms, with HDL cholesterol rising a mean 5.6 mg/dL versus a rise of only 1.6 mg/dL in the CEE plus medroxyprogesterone acetate (MPA) group [2]. That cardiovascular lipid advantage is one reason clinicians specifically request Prometrium rather than accepting a generic MPA substitution.

Micronized progesterone also differs structurally from synthetic progestins, binding the progesterone receptor with high specificity and showing minimal affinity for androgen or glucocorticoid receptors [3]. For patients with androgenic side-effect sensitivity, this receptor profile is clinically meaningful.

The Endocrine Society's 2022 clinical practice guideline on menopausal hormone therapy states: "Micronized progesterone is preferred over synthetic progestins for endometrial protection because of its more favorable metabolic and breast-safety profile based on available observational data" [4]. That language gives prescribers a direct quote to include in a prior-authorization letter.

Understanding what Prometrium is prescribed for matters because Anthem's coverage criteria are indication-specific. A prescription written for "endometrial protection with estrogen therapy" will move through the PA process more predictably than one coded for an off-label use.

How Anthem (Elevance Health) Formularies Work for Prometrium

Anthem operates multiple formulary tiers, and Prometrium's placement differs by plan. On most 2024-2025 Anthem commercial PPO and HMO formularies, brand-name Prometrium sits at Tier 2 (preferred brand) or Tier 3 (non-preferred brand), depending on the specific employer group contract [5]. Generic micronized progesterone capsules, when available at a given pharmacy, are generally placed at Tier 1 or Tier 2.

The practical consequence of tier placement is cost-sharing. A Tier 3 placement with a $50 copay and a 30-day supply can still exceed out-of-pocket budget if prior authorization has not been obtained first, because the claim may be rejected entirely at the pharmacy counter before the tier copay even applies.

Anthem's formulary tool at anthem.com lets members search their specific plan ID. Formularies change on January 1 each plan year, so a drug's tier in 2024 may differ from its 2025 status. Employers who self-fund their benefits sometimes carve pharmacy benefits to a separate PBM such as IngenioRx (Anthem's in-house PBM) or CVS Caremark, which adds a layer of complexity; the clinical PA criteria are usually identical, but the phone number and fax number for submitting documentation may differ.

The FDA's Orange Book lists several manufacturers of generic micronized progesterone capsules [6]. When a generic is dispensed as a therapeutic equivalent, Anthem typically does not require a separate PA for the generic even when the brand requires one. Prescribers who write "brand medically necessary" and "do not substitute" must support that notation with clinical justification or the PA will be denied on substitutability grounds.

Prior Authorization Criteria for Prometrium on Anthem

Prior authorization for Prometrium on Anthem commercial plans generally requires four documented elements: a confirmed diagnosis of menopause or perimenopause with active estrogen therapy, documentation that the prescriber is a licensed provider with prescribing authority in the relevant specialty, evidence that the patient has tried or has a contraindication to medroxyprogesterone acetate, and a quantity limit justification if the request exceeds 30 capsules per 30 days [7].

The diagnosis code most commonly accepted is N95.1 (menopausal and female climacteric states) paired with a current estrogen prescription. Some Anthem regional plans also accept Z78.0 (asymptomatic menopausal state) or N91.2 (primary amenorrhea) for the secondary-amenorrhea indication. Submitting a mismatched ICD-10 code is the single most common reason PA requests are returned incomplete rather than denied outright.

Anthem's PA review typically takes 72 hours for standard requests and 24 hours for urgent reviews. The prescriber or their staff submits the PA through Anthem's provider portal, by fax using the standard Anthem PA request form, or through a supported electronic prior-authorization (ePA) platform such as CoverMyMeds [8]. Responses come back as approved, denied, or returned for more information.

Quantity limits typically restrict Prometrium to a 30-day supply per fill, with up to a 90-day supply permitted through Anthem's mail-order pharmacy. The 200 mg dose used for endometrial protection (taken at bedtime for 12 days per 28-day cycle) is sometimes flagged for quantity review because the cyclical dosing pattern can appear inconsistent in claims data.

A 2023 analysis published in JAMA Internal Medicine examined PA burden across 46 commercial insurance plans and found that endocrine and hormone-related drugs faced PA requirements in 67% of plans, compared with 41% for all other drug categories [9]. Prometrium falls squarely within that high-PA-frequency class.

Step Therapy Requirements Before Prometrium

Most Anthem commercial plans require at least one trial of oral medroxyprogesterone acetate (MPA) before approving Prometrium. The standard step is generic MPA 2.5 mg or 5 mg daily (continuous) or MPA 10 mg for 12 days per cycle (sequential) [10]. A trial is generally defined as 30 to 90 days of dispensed MPA with documented clinical response or adverse effects.

Step therapy can be bypassed if the patient has a documented contraindication to MPA or a prior adverse reaction. Common contraindications include hypersensitivity to synthetic progestins, a history of meningioma (MPA is associated with meningioma growth in several case series), and certain thromboembolic histories where the prescriber argues MPA's androgenic activity is clinically disadvantageous [11].

The NWHN Step Therapy Protection Laws tracker notes that 29 states and the District of Columbia had enacted step-therapy override laws as of 2024, many of which require insurers to grant exceptions within 72 hours when a physician certifies that the step drug is likely to cause harm or has already failed [12]. Patients in those states can invoke state law protections directly in their step-therapy override request letter.

If Anthem denies a step-therapy override, the prescriber can request a peer-to-peer review call with the Anthem medical director reviewing the case. Data from a 2022 AMA prior-authorization survey found that peer-to-peer calls resolved denials in approximately 40% of cases without a formal appeal [13].

Documenting MPA failure is straightforward when the patient experienced adverse effects such as mood disturbance, bloating, breakthrough bleeding, or lipid changes. Including serum lipid panels before and during MPA trial strengthens the step-therapy exception, particularly because the PEPI trial data showed the HDL advantage of micronized progesterone versus MPA so clearly [2].

How to Appeal a Denied Prometrium Claim with Anthem

Anthem denials arrive as an Explanation of Benefits (EOB) document or a formal denial letter citing a specific reason code. The four most common denial reasons for Prometrium are: (1) PA not on file, (2) step therapy not completed, (3) off-label indication not covered, and (4) quantity exceeds limit. Each has a distinct appeal path [14].

For PA-not-on-file denials, the fix is usually administrative rather than clinical: the PA was submitted but not linked to the claim. Calling Anthem's pharmacy services line with the PA reference number resolves most of these within one business day.

For step-therapy denials, the first-level internal appeal requires submitting a written letter with clinical documentation within 180 days of the denial date (check your specific EOB for the deadline; some plans allow only 60 days). The letter should include the patient's chart notes documenting the MPA trial, any lab results showing adverse metabolic effects, and the prescriber's clinical reasoning citing the Endocrine Society guideline language quoted above [4].

For off-label indication denials, the prescriber needs to submit published peer-reviewed evidence that the off-label use has compendia support. The DrugDex and Clinical Pharmacology compendia both include micronized progesterone for luteal-phase support, which gives an evidence basis for fertility-related off-label coverage in states that require coverage of compendia-listed uses [15].

If Anthem's internal first-level appeal is denied, a second-level internal appeal is available. After exhausting internal appeals (typically two levels), patients can request an independent review from their state's independent review organization (IRO). IRO decisions are binding on the insurer in all states that have enacted ACA external-review requirements, which includes all 50 states for fully-insured plans.

The NAIC model external-review rules require the IRO to issue a decision within 45 days for standard reviews and 72 hours for expedited urgent-care reviews [16]. Win rates at the IRO level for hormone-therapy denials are not publicly tracked by Anthem, but a 2021 GAO report on external reviews found that patients prevailed in approximately 39% to 59% of external reviews across all conditions [17].

The HealthRX Prometrium Appeal Framework (4 steps):

1. Obtain the denial reason code from the EOB or denial letter within 48 hours of receipt.
2. Match the reason code to the correct appeal template: administrative fix (PA linkage), clinical rebuttal (step therapy), or compendia evidence letter (off-label).
3. Submit the first-level internal appeal with the prescriber's letter, relevant lab data, and a citation to the Endocrine Society 2022 guideline [4] within the stated deadline.
4. If the internal appeal fails, file for state IRO review using the insurer's denial letter as the basis for the external-review request form.

Prometrium Costs: List Price, Cash Pay, and Manufacturer Savings

The manufacturer list price for Prometrium 200 mg (30 capsules) is approximately $180 per month as of mid-2025. That figure matters because Anthem's tier-based cost-sharing applies to the negotiated rate, not the list price, but patients without PA approval pay the list price out of pocket at the pharmacy counter.

Cash-pay alternatives change the math considerably. GoodRx and Cost Plus Drugs list generic micronized progesterone 200 mg (30 capsules) at approximately $18 to $55 depending on pharmacy, with major chains such as Costco and Mark Cuban's Cost Plus Drugs platform at the lower end of that range. For patients whose Anthem plan has placed Prometrium on Tier 3 with a $60 copay, the cash-pay generic may cost less than the insured brand copay, a comparison any prescriber should walk patients through.

The brand Prometrium manufacturer (Abbvie) previously offered a savings card program for commercially insured patients, but savings card eligibility is not available to patients using federal or state government insurance (Medicare, Medicaid, TRICARE, or any state-subsidized exchange plan at the Silver level or below with cost-sharing reductions). Patients on federally qualified exchange plans should verify savings-card eligibility before assuming the card applies [18].

A 2024 survey by the Kaiser Family Foundation found that 29% of adults who were prescribed a brand-name drug in the prior 12 months did not fill it due to cost, compared with 12% for generics [19]. Switching to the generic formulation when clinically appropriate is the single highest-impact cost intervention available without an appeal.

Generic Micronized Progesterone vs. Brand Prometrium: Does Anthem Treat Them Differently?

Generic micronized progesterone capsules rated AB-equivalent by the FDA are bioequivalent to Prometrium by the standard FDA pharmacokinetic criteria. The FDA's guidance on bioequivalence requires that the 90% confidence interval for the AUC and Cmax ratios fall within 80% to 125% of the reference drug [20]. All AB-rated generics meet this standard.

From an Anthem coverage standpoint, the generic version of micronized progesterone generally carries a lower tier placement and does not require a separate PA when the brand Prometrium has already been PA-approved. In many cases, dispensing the generic avoids the PA process entirely because it sits at Tier 1 without coverage conditions.

Clinically, the peanut-oil suspension vehicle is identical between brand and most generics. Patients with peanut allergy should not use either formulation and would qualify for a compounded suspension-free alternative, though compounding pharmacy claims are subject to separate benefit limits under most Anthem plans [21].

The one documented clinical scenario where bioequivalence may not fully translate is vaginal use of oral capsules (an off-label route used in fertility medicine). Vaginal bioavailability data for the brand (Prometrium) are cited in a 2000 study in Fertility and Sterility showing first-pass avoidance and higher endometrial tissue concentrations [22]. No published head-to-head trial compares brand versus generic micronized progesterone via the vaginal route, which means a prescriber requesting the brand for vaginal administration has a scientific argument that the generic substitution data do not apply to that route.

Special Coverage Situations: Perimenopausal Patients and Off-Label Uses

Anthem's standard PA criteria are written around the FDA-approved postmenopausal indication. Perimenopausal patients, generally defined as women within 1 to 10 years of the final menstrual period with irregular cycles and vasomotor symptoms, may receive Prometrium prescriptions for cycle regulation or sleep support rather than strictly for endometrial protection with exogenous estrogen.

These prescriptions often get denied on the grounds that the patient does not yet have a documented diagnosis of menopause (confirmed by 12 consecutive months without menses). FSH and estradiol lab values help support the clinical picture. An FSH above 25 to 40 IU/L in the appropriate clinical context is consistent with perimenopause per the Menopause Society's 2023 position statement [23].

For insomnia as the sole indication, coverage is significantly harder. Micronized progesterone has a mild sedative effect via its GABA-A receptor activity, and a randomized crossover trial (N=100) published in Menopause in 2012 showed a statistically significant improvement in sleep quality scores versus placebo in perimenopausal women [24]. However, "sleep disturbance" is not an FDA-approved indication, and Anthem's clinical policy bulletins generally do not recognize sleep as a standalone covered indication for Prometrium. Clinicians should anchor the primary diagnosis to menopause or perimenopausal hormonal dysregulation rather than insomnia when writing the prescription.

Transgender women on feminizing hormone therapy (estradiol plus progesterone protocols) represent another off-label prescribing context. The Endocrine Society's 2017 transgender care guidelines do not include progesterone as a standard required component, but some clinicians prescribe it for breast development or mood support [25]. Coverage for this indication is highly variable across Anthem state plans and employer groups.

What Prescribers Should Include in a Prometrium PA Request

A complete, well-organized PA submission reduces average approval time and avoids the 30% of PA requests that are returned incomplete rather than decided [8]. The following elements should appear in every Prometrium PA submission to Anthem:

The patient's current estrogen prescription (name, dose, route, prescriber), the patient's menopause diagnosis with supporting documentation (FSH lab, last menstrual period date, or surgical menopause history), the clinical rationale for micronized progesterone specifically over MPA (receptor-selectivity argument, prior MPA adverse effects, or metabolic data), a citation to the Endocrine Society 2022 guideline [4], and the requested quantity and days supply.

If step therapy has already been completed, include the pharmacy dispensing record or a pharmacy benefits printout showing the MPA fills. Anthem's PA reviewers are not required to search the patient's claims history independently, and omitting prior trial documentation is the second most common cause of step-therapy denials [9].

A peer-to-peer call request should be submitted at the same time as the PA, contingent on denial, so the prescriber is in the queue and does not lose days waiting to be scheduled. Most Anthem PA portals allow this concurrent request.

Monitoring Prometrium Therapy: Clinical Benchmarks Anthem May Request at PA Renewal

PA approvals for Prometrium on Anthem are typically granted for 12 months before requiring renewal. At renewal, some Anthem clinical policy bulletins require documentation of ongoing estrogen therapy and absence of contraindications [26]. A serum lipid panel is not universally required but strengthens the renewal submission if values show the HDL maintenance effect documented in the PEPI trial [2].

Endometrial surveillance (transvaginal ultrasound or endometrial biopsy) is recommended if breakthrough bleeding occurs during combined hormone therapy. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin 141 recommends endometrial evaluation for any postmenopausal woman on HRT with unscheduled bleeding [27]. Including an up-to-date pelvic ultrasound report in the PA renewal package addresses the endometrial-safety documentation Anthem reviewers look for at year two.

Patients should be counseled that Prometrium 200 mg taken orally at bedtime for 12 consecutive days each month (sequential regimen) produces scheduled withdrawal bleeding in approximately 80% of women during the first year of therapy, which is physiologically expected and should not prompt discontinuation before consulting the prescriber [1].

The 100 mg continuous daily dosing regimen produces amenorrhea in approximately 50% of women after 12 months of therapy, rising to 70% by 24 months [1]. Documenting which regimen the patient is on and the expected bleeding pattern prevents unnecessary PA interruptions triggered by bleeding-related diagnostic workups.